Working hours during Carnival at FIOCRUZ
On Friday (February 13), the eve of Carnival, Fiocruz will operate remotely.
During Carnival week, there will be optional working hours on Monday (February 16) and Tuesday (February 17).
On Wednesday (February 18), work will be remote from 2 p.m. onwards.
These measures do not apply to essential services, which will operate normally. The Fiocruz Daycare Center and Nust/CST will not be open for in-person service between February 13 and February 18.

Working hours during Carnival at ReBEC/FIOCRUZ

SYSTEM AND CHAT SERVICE REBEC@
The ReBEC platform remains in operation 24 hours a day, every day of the week, with service provided by AI ReBEC@. 

CHAT AND HUMAN SERVICE
Human service follows the special operating hours determined by Fiocruz for Carnival. On Friday (February 13), the eve of Carnival, remote working from 8 a.m. to 5 p.m. During Carnival week, optional working on February 16 and 17. On Wednesday, February 18, remote working from 2 p.m. Human service hours will return to normal from Thursday, February 19.

PRIORITY SERVICES

The Brazilian Registry of Clinical Trials (ReBEC) presents the new fast tracks for clinical research and observational studies on INDIGENOUS PEOPLE AND TRADITIONAL COMMUNITIES and on NEGLECTED TROPICAL DISEASES (NTDs). Fast-track can reduce the normal approval period for clinical trials to less than 48 hours, if the documentation, information and any mandatory changes requested are provided by the registrant.

The already existing fast-tracks and the attendance to other studies will not be interrupted. Priority care is granted with a view to accelerating clinical research in epidemiological emergency situations and/or studies with the potential to reduce socioeconomic inequalities, keeping the perspective aligned with the forefront of ethics and transparency, diplomacy in health, scientific collaboration and diversity and specificities of recruitment and health care.

FAST-TRACKS IN OPERATION:

I - Indigenous Peoples, Traditional Communities, Human Migration and Refugee Movements – clinical research and observational studies dedicated to or preferably addressing traditional communities (quilombola, caiçara, faxinalense, among others), Indigenous peoples (within or outside legally demarcated territories), and refugee groups, taking into account the specificities established by regulation, on a case-by-case basis.

II - Neglected Tropical Diseases – Leprosy, Tuberculosis, Leishmaniasis, Schistosomiasis, Scabies, Chagas disease, Intestinal parasitoses, Viral hepatitis, Trachoma, Onchocerciasis, Human rabies transmitted by dogs.

III - National and International Public Health Emergencies – Mpox, Covid-19.

IV - Arboviruses – Zika, Dengue, Chikungunya, Malaria, Yellow fever.

V - WHO Prioritized Pathogens for Latin America – Studies dealing with World Health Organization prioritized pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Lassa fever, Cholera, Black Death (Plague), Bacillary dysentery or Shigellosis, Salmonella, Pneumonia, Urinary tract infection, MERS-CoV, SARS, Ebola virus (EVE), Marburg virus (MVE), Ebola virus (EVE) Sudan subtype, Hantavirus pulmonary syndrome (HPS), Hemorrhagic fever with renal syndrome (HFRS), Crimean-Congo hemorrhagic fever, Influenza A H1, Influenza A H2, Influenza A H3, Avian influenza (Influenza A H5N1), Avian influenza (Influenza A H6), Avian influenza H7 (Avian influenza H7), Avian influenza H10 or Avian influenza H10, Nipah disease, Viral hemorrhagic disease, Poliomyelitis, Hand-foot-and-mouth disease, Herpangina, Viral meningitis, Smallpox, Mpox, Human Immunodeficiency Virus (HIV), Venezuelan equine encephalitis (VEE).

VI - WHO Prioritized Prototype Pathogens for Latin America – Studies dealing with World Health Organization prioritized prototype pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Recombinant mastadenovirus, Mastadenovirus blackbeardi serotype 14, Mammarenavirus juninense, Mammarenavirus lujoense, Mamastrovirus virginiaense, Orthobornavirus bornaense, Orthoflavivirus encephalitidis, Orthoflavivirus nilense, Orthohepadnavirus hominoidae genotype C, Paslahepevirus balayani genotype 3, Protoparvovirus carnivoran, Orthobunyavirus oropoucheense, Phlebovirus riftense, Orthopicobirnavirus hominis, Enterovirus alphacoxsackie 71, Enterovirus deconjuncti 68, Metapneumovirus hominis, Orthopoxvirus vaccinia, Genus Vesiculovirus, Genus Rotavirus, Orthoreovirus mammalis.

VII - Studies on the impacts of climate change, the effects of scientific denialism, and health misinformation -The physical, mental, and social consequences of environmental and climate changes on human populations; The impact of extreme weather events and environmental degradation on infectious, chronic, or emerging diseases; The influence of denialist narratives and misinformation in Health on adherence to preventive measures, vaccination, treatments, and risk behaviors, as well as the physical and mental outcomes for human beings and populations.

INSTRUCTIONS:

We recommend reading the Registrant Handbook. Material available at LINK.

1. Register or log in and normally fill out the forms in Portuguese and English. For English, in case of difficulty, use the Google Translate tool (or another free translation tool).
2. Attach the mandatory ethics committee documentation and submit the form.
3. Register the service number on your Whatsapp. Send a message with your name and login. IT IS NOT NECESSARY NOR RECOMMENDED TO SEND YOUR PASSWORD.
4. A reviewer will respond to you. Choose the service modality: chat, audio recordings or voice call by appointment.
5. Your form will be proofread in both languages. Follow the remaining guidelines to finalize the approval.

CONTACTS:

Support is online, via chat, dedicated telephone line (see phone number below) and WhatsApp, from 9 am to 5 pm (Brasília time).

Administrative, priority and/or urgent matters outside office hours: plantao.rebec@gmail.com
Line 1: +55 21 97203-4750

ABOUT REBEC:

The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (OPAS) and the Oswaldo Cruz Foundation (FIOCRUZ). ReBEC's Executive Committee is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA).

02/23/2026 | Jessica Bernardo | Metrópolis

https://www.metropoles.com/sao-paulo/butantan-antecipara-entrega-de-13-milhao-de-doses-da-vacina-da-dengue 

Vaccine, which was scheduled for delivery in the second half of the year, should arrive at the Ministry of Health by the end of June.

The Butantan Institute will advance the delivery of 1.3 million doses of the dengue vaccine, Butantan-DV, to the Ministry of Health. The shipment of immunizing agents was only scheduled for the second half of this year.

The information was announced this Monday (February 23rd) by Governor Tarcísio de Freitas (Republicanos) and the director of the Butantan Institute, Esper Kállas, at the ceremony marking the 125th anniversary of Butantan, at the institution's headquarters in the western part of São Paulo.

“We are going to bring forward 1.3 million doses that were planned for the second semester and will now deliver them in the first semester. Starting with 200,000 doses that will be delivered this February,” stated Tarcísio.

In total, the Ministry of Health contracted the production of 3.9 million doses of the vaccine with Butantan, for R$ 368 million. The first shipment, also of 1.3 million vaccines, was completed in January of this year. The last batch of contracted vaccines should arrive at the Ministry of Health in 2027.

02/25/2026 | Janine Russczyk | Ministry of Health

https://www.gov.br/saude/pt-br/assuntos/noticias/2026/fevereiro/ministerio-da-saude-recebe-contribuicoes-para-desenvolver-a-nova-plataforma-de-pesquisas-que-envolvem-seres-humanos 

Improvement is strategic to modernize, qualify, and strengthen ethical research processes in Brazil

The Ministry of Health has made available an electronic form to receive suggestions that will support the development of the new research platform involving human subjects in Brazil. This initiative is part of the efforts implemented by the Ministry to broaden social participation and consolidate an even more ethical, transparent, and safe environment for conducting research. The information will be used in the construction of the new registry database, replacing the Plataforma Brasil.

The new platform is a strategy to modernize and improve the database. To achieve this, it relies on the involvement of the scientific community, managers, representatives of society, and stakeholders in health research, who contribute from the initial stages by sharing experiences and indicating needs and priorities. With the collection of input and the involvement of participants, the Ministry will establish a collaborative network with the active participation of stakeholders in different phases of conception, development, testing, and validation of the new platform.

The Secretary of Science, Technology and Innovation in Health of the Ministry of Health, Fernanda De Negri, emphasized that the action is in accordance with the Law on Research with Human Beings (Law 14.874/2024), which was recently regulated to align the country with global standards of innovation and ethics (Decree 12.651/2025). In this context,…

02/25/2026 | Daniel Negreiros Conceição and Lucien | Le Monde Diplomatique Brazil

https://diplomatique.org.br/polilaminina-e-o-fetiche-do-placebo-em-pesquisas-de-alto-risco/ 

The debate on new therapies for spinal cord injuries reveals a fundamental tension between methodological rigor and ethical responsibility.

I watched my colleague Tatiana Sampaio's interview on the Roda Viva program and was immensely disturbed. I confess that I wasn't paying much attention to the debate that kept appearing in my news clippings. For me, it was enough to know that a possible treatment for devastating spinal cord injuries had been discovered thanks to the responsibly creative scientific research of a brilliant colleague from UFRJ. But, watching the interview, I was immediately reminded of the ceremonial barriers that are usually imposed on novelty, even in environments that claim to be averse to dogmatism. Some interviewers seemed more interested in denouncing a supposed technical inadequacy of the preliminary studies due to the lack of a randomly selected control group (without treatment) for a statistically “clean” comparison with the treatment group. As a heterodox economist and proponent of Modern Monetary Theory (MMT), I have experienced this type of conservatism disguised as scientific zeal more than once.

The argument of Tatiana Sampaio's critics is well-known: the absence of randomized control groups would invalidate any robust causal inference. This is a methodologically reasonable objection in the abstract, but ethically very weak when examined in the concrete context of the research.

Spinal cord injuries do not constitute a “neutral baseline state.” They are catastrophic, largely irreversible events in which the therapeutic window is extremely short. In this…

02/23/2026 | Novo Nordisk and Estadão Blue Studio

https://www.estadao.com.br/saude/inovacao-em-saude-esbarra-na-falta-de-previsibilidade-no-brasil/ 

According to experts and healthcare companies, regulatory and legal barriers affect long-term investments, clinical research, and patient access to new treatments

Innovation in healthcare is not just about developing new molecules or technologies. It is about ensuring that scientific knowledge can navigate a long, complex, and uncertain path to reach the patient. In Brazil, this path still faces regulatory and legal barriers that compromise the predictability needed to sustain long-term investments in research and development. The result, experts warn, is felt at the end of the line: delayed access to innovations and fewer opportunities for patients to participate in cutting-edge clinical research.

The discussion on regulatory predictability has gained ground in public debate and in the healthcare sector, as global companies assess the Brazilian environment for long-term investments in science. For Danish pharmaceutical company Novo Nordisk, which has been present in the country for decades, the issue goes beyond the pharmaceutical sector and affects the entire national scientific production ecosystem.

Clear rules
According to Leonardo Bia, Vice President of Corporate Affairs and Sustainability at Novo Nordisk Brazil, innovation only thrives when it finds a solid institutional environment. “Innovation depends on an ecosystem that allows it to flourish. This only happens when there is predictability and security at all stages, both legislative and legal,” he says. For him, Brazil's recognition as a reliable environment for investment is crucial for research projects to move forward.

This security,…

02/24/2026 | Claudio Marques | Viva.com

https://viva.com.br/carreira-e-educacao/emergencias-sanitarias-curso-internacional-com-oxford-abre-25-vagas-no-brasil.html 

Health professionals who wish to strengthen their skills in clinical research focused on infectious diseases and join a global network of professionals who work on the front lines of preparing and responding to epidemics are waiting for this fifth fair (02/26) to launch the international Clinical Research During Outbreaks (CREDO) program. Brazil 2026.

The CREDO course (or Pesquisa Clínica Durante Surtos, in Portuguese) is an internationally recognized training program designed for health and medical professionals. researchers, which combines practical learning, international exchange and applied research planning.

Coordinated in Brazil by Instituto D'Or de Pesquisa e Ensino (IDOR), the program integrates a global network led by ISARIC, in partnership with the University of Oxford, or the Special Program for Research and Training in Tropical Doenças of the World Health Organization (WHO/TDR) and Fiocruz.

ISARIC is an acronym for International Severe Acute Respiratory and Emerging Infection Consortium. This is a global federation of clinical research networks that work to prevent deaths and diseases caused by outbreaks of infectious diseases.

The course was created with the objective of training researchers and health professionals capable of planning and conducting clinical studies in emergency contexts, such as in the case of pandemics, with methodological rigor, adequate governance, data management and international ethical guidance.

The training, from March to June 2026, will be held in English and offers 25 free sessions for Brazil, with financial support for the in-person workshop in Salvador…